专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

121. 发明专利

BRPI0720282A2 未知
公开(公告)号：BRPI0720282A2
公开(公告)日：2014-01-28
申请号：BRPI0720282
申请日：2007-12-14
申请人： BAXTER INT , BAXTER HEALTHCARE SA
发明人： TURECEK PETER , SIEKMANN JUERGEN , SCHEIFLINGER FRIEDRICH , CANAVAGGIO MICHEL
IPC分类号： A61K47/48
摘要： The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (F Vila) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.

122. 发明专利

CA2838845A1 TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF 未知
公开(公告)号：CA2838845A1
公开(公告)日：2012-12-13
申请号：CA2838845
申请日：2012-06-11
申请人： BAXTER INT , BAXTER HEALTHCARE SA
发明人： SCHEIFLINGER FRIEDRICH , TURECEK PETER , EWENSTEIN BRUCE , WONG WING YEN , SUITER TOBIAS M
IPC分类号： A61K38/36 , A61K38/37 , A61P7/04
摘要： The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII.

123. 发明专利

NZ588200A PROCOAGULANT PEPTIDES 未知
公开(公告)号：NZ588200A
公开(公告)日：2012-11-30
申请号：NZ58820009
申请日：2009-04-16
申请人： BAXTER HEALTHCARE SA , BAXTER INT
发明人： DOCKAL MICHAEL , SCHEIFLINGER FRIEDRICH
IPC分类号： C07K7/06 , C07K7/08
摘要： Provided is a pro-coagulant peptide or a peptide derivative comprising the sequence motif WDLYFEIVW or its variant amino acid sequence comprising one, two, three or four amino acid substitutions in specified locations and to specified amino acids, or the retro-inverso variant of the aforementioned peptides. The peptides can be used to treat haemophilia diseases with a deficiency of factors FV, FVII, FVIII, FX and/or FXI.

124. 发明专利

AU2008209986B2 FVIII-independent FIX-mutant proteins for hemophilia A treatment 未知
公开(公告)号：AU2008209986B2
公开(公告)日：2012-11-08
申请号：AU2008209986
申请日：2008-01-29
申请人： BAXTER HEALTHCARE SA , BAXTER INT
发明人： SCHEIFLINGER FRIEDRICH , DOCKAL MICHAEL , HARTMANN RUDOLF
IPC分类号： C12N9/64 , A61K38/36
摘要： The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having factor VIII (FVIII) independent factor X (FX) activation potential. Five full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK 293 cells. The proteins were tested by an activated partial thromboplastin time (aPTT) assay in FVIII-depleted plasma as well as in FVIII-inhibited patient plasma. In FVIII-depleted plasma functional activity of the FIX mutants was calculated as increased FVIII equivalent activity. The mutant proteins had increased FVIII equivalent activity. In FVIII-inhibited patient plasma the FEIBA equivalent activity was calculated for analysis of FVIII independent FX activation potential. The proteins had also increased FEIBA equivalent activity. Furthermore, the pre-activated FIX proteins had an increased activity in FIX-depleted plasma containing FVIII inhibitors. Therefore these FIX mutants are alternatives as bypassing agents for treatment of FVIII inhibitor patients.

125. 发明专利

AU2012205202A1 Biologically Active Peptides 未知
公开(公告)号：AU2012205202A1
公开(公告)日：2012-08-09
申请号：AU2012205202
申请日：2012-07-18
申请人： BAXTER INT , BAXTER HEALTHCARE SA
发明人： SCHEIFLINGER FRIEDRICH , DOCKAL MICHAEL
IPC分类号： C07K7/06 , C07K7/08
摘要： A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1 ); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1 ); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.

126. 发明专利

NZ586600A ANTI MACROPHAGE MIGRATION INHIBITORY FACTOR ANTIBODIES 未知
公开(公告)号：NZ586600A
公开(公告)日：2012-05-25
申请号：NZ58660008
申请日：2008-12-30
申请人： BAXTER INT , BAXTER HEALTHCARE SA , DYAX CORP
发明人： KERSCHBAUMER RANDOLF , SCHEIFLINGER FRIEDRICH , RIEGER MANFRED , THIELE MICHAEL , MUDDE C
IPC分类号： A61K39/395 , A61P1/00 , A61P13/12 , A61P35/00 , C07K16/24 , C12N15/13
摘要： Disclosed is a monoclonal antibody or an antigen-binding portion thereof that specifically binds to the center region of macrophage migration inhibitory factor (MIF) and inhibits human MIF biological function, wherein the center region is the region spanning aa 50-68 of human MIF. Also disclosed is the use of the antibody in the manufacture of a medicament for treating an immunological disease in a subject.

127. 发明专利

CA2793465A1 TFPI INHIBITORS AND METHODS OF USE 未知
公开(公告)号：CA2793465A1
公开(公告)日：2011-09-22
申请号：CA2793465
申请日：2011-02-11
申请人： BAXTER INT , BAXTER HEALTHCARE SA
发明人： DOCKAL MICHAEL , HARTMANN RUDOLF , FRIES MARKUS , SCHEIFLINGER FRIEDRICH , EHRLICH HARTMUT , REINEKE ULRICH , OSTERKAMP FRANK , POLAKOWSKI THOMAS
IPC分类号： A61K38/18 , A61K38/16 , C40B40/10
摘要： The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.

128. 发明专利

AU2009284393A1 Methods for treating bleeding disorders 未知
公开(公告)号：AU2009284393A1
公开(公告)日：2010-02-25
申请号：AU2009284393
申请日：2009-08-21
申请人： BAXTER INT , BAXTER HEALTHCARE SA
发明人： DOCKAL MICHAEL , SCHEIFLINGER FRIEDRICH , TURECEK PETER
IPC分类号： A61K31/737 , A61K31/727 , A61P7/04
摘要： A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor X1; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor X1-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI.

129. 发明专利

CA2712474A1 PROCEDURE FOR THE GENERATION OF A HIGH PRODUCER CELL LINE FOR THE EXPRESSION OF A RECOMBINANT ANTI-CD34 ANTIBODY 未知
公开(公告)号：CA2712474A1
公开(公告)日：2009-08-27
申请号：CA2712474
申请日：2009-02-19
申请人： BAXTER HEALTHCARE SA , BAXTER INT
发明人： KERSCHBAUMER RANDOLF , BOECK-TAFERNER PETRA , SCHEIFLINGER FRIEDRICH
IPC分类号： C07K16/28 , A61K39/395
摘要： Procedure for verifying the integrity of documents which comprises a characterization of the original document to obtain a hash (508) and a stage of integrity verification, this stage comprising in turn, representing (601) the digital document to be verified in a matrix format; adapting (602) said document to a determined resolution in the characterization and correcting (603) the inclination, obtaining a corrected image (604); obtaining (605), the displacement produced between the contents in the original document and the document to be verified; obtaining (610) optimal displacement coordinates for each one of the regions of the corrected image; obtaining (611 ) one metric from the quantified coefficients of the corrected image and the corresponding ones in the original document; deciding (612) on the integrity of each region of the digitalized document using the previous metrics; and finally deciding (613) on the integrity of the document based on the results of the previous step.

130. 发明专利

CA2711029A1 ANTI MIF ANTIBODIES 未知
公开(公告)号：CA2711029A1
公开(公告)日：2009-07-16
申请号：CA2711029
申请日：2008-12-30
申请人： BAXTER HEALTHCARE SA , BAXTER INT , DYAX CORP
发明人： KERSCHBAUMER RANDOLF , SCHEIFLINGER FRIEDRICH , RIEGER MANFRED , THIELE MICHAEL , MUDDE C GEERT , MUELLBERG JUERGEN , HOET RENE
IPC分类号： C07K16/24 , A61K39/395 , A61P1/00 , A61P13/12 , A61P35/00 , C12N15/13
摘要： The present application relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The application also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present application also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式